North America Liquid Biopsy Market - Trends and Forecast Till 2035

NORTH AMERICA LIQUID BIOPSY MARKET: OVERVIEW

The North America liquid biopsy market is estimated at USD 5.2 billion in the current year and is projected to reach USD 17.4 billion by 2035, representing a CAGR of 14.4% during the forecast period.

North America Liquid Biopsy Market: Growth and Trends Shaping the Market

Liquid biopsy involves analyzing blood, plasma, or other bodily fluids to detect tumor-derived biomarkers, including circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), cell-free RNA (cfRNA), circulating tumor cells (CTCs), and exosomes. Unlike tissue biopsy, which requires an invasive procedure and is often unsuitable for repeat sampling, liquid biopsy can be performed longitudinally with minimal patient burden. This makes it particularly valuable for early cancer detection, therapy selection, treatment-response monitoring, minimal residual disease (MRD) assessment, and recurrence surveillance.

Adoption of liquid biopsy testing in North America is accelerating due to the growing cancer burden, an advanced oncology care infrastructure, an increasingly favorable reimbursement environment, and the industry-wide shift toward precision, biomarker-guided medicine. In the United States alone, an estimated 2.11 million new cancer cases and 626,140 cancer deaths are projected this year, reinforcing the clinical need for scalable, minimally invasive, and repeatable diagnostic tools.

The region has also seen a series of regulatory milestones that have strengthened clinical and commercial confidence in blood-based genomic testing. FDA approvals such as Guardant360 CDx for comprehensive tumor mutation profiling and FoundationOne Liquid CDx as a next-generation sequencing (NGS)-based companion diagnostic have helped liquid biopsy as a mainstream component of the North America oncology precision-medicine ecosystem, rather than an emerging or experimental modality.

Growth Drivers: Factors Fueling Market Expansion

• Preference for minimally invasive testing: Liquid biopsy offers a patient-friendly alternative to tissue biopsy, particularly for patients with advanced disease, hard-to-access tumors, or a clinical need for repeated molecular monitoring.
• Expanding precision oncology adoption: Oncologists increasingly rely on blood-based genomic profiling to identify actionable mutations, guide targeted-therapy selection, and track emerging resistance mechanisms, especially when tissue samples are insufficient or unavailable.
• Regulatory validation and companion diagnostic approvals: A growing list of FDA-cleared and FDA-approved liquid biopsy assays is reinforcing clinical trust and accelerating integration into standard-of-care pathways.
• Rising demand for MRD and recurrence monitoring: Post-treatment surveillance protocols increasingly rely on ctDNA-based assays to detect relapse earlier than imaging or conventional tumor markers.
• Technology advancement: Continuous improvements in NGS throughput, turnaround time, and per-test cost are expanding the range of clinically and commercially viable liquid biopsy applications.

Market Challenges: Critical Barriers Hindering Progress

• Limited Sensitivity in Early-Stage Detection: At very early disease stages, circulating tumor DNA and related biomarkers can be present at extremely low concentrations, raising the risk of false-negative results and constraining broader use in population-level screening.
• Risk of False Positives from Biological Noise: Age-related clonal hematopoiesis and other non-tumor genetic alterations can be misread as tumor-derived signals, complicating result interpretation and creating a need for careful assay validation.
• Cost and Reimbursement Variability: Comprehensive genomic profiling and multi-cancer early detection tests remain relatively expensive, and reimbursement pathways for newer indications are still maturing in several care settings.
• Standardization Across a Fast-Evolving Assay Landscape: As new multi-cancer early detection (MCED) and MRD platforms enter the market, laboratories and health systems face an increasingly complex task of validating and standardizing testing protocols.

Recent Developments Signaling Market Momentum

• Caris Life Sciences commercially launched Caris Detect™, a multi-cancer early detection blood test in the US that combines ultra-deep whole-genome and whole-transcriptome sequencing with AI-based signal detection, extending liquid biopsy use beyond advanced-cancer profiling into early detection.
• UnitedHealth Group began reimbursing Guardant Health's Shield blood-based colorectal cancer screening test for eligible members aged 45 and older, extending covered lives for the test to more than 100 million and supporting broader non-invasive CRC screening adoption.
• Quest Diagnostics received New York State Department of Health CLEP approval for Haystack MRD, its ctDNA-based test for minimal residual disease detection, making the assay available for patient testing across all 50 US states.
• Foundation Medicine secured FDA approval for FoundationOne Liquid CDx as a companion diagnostic supporting a Talzenna-Xtandi combination therapy in HRR gene-mutated metastatic castration-resistant prostate cancer, extending blood-based profiling into therapy-selection use cases.

North America Liquid Biopsy Market Segments

The market opportunity has been segmented across the following parameters, providing a structured framework for opportunity sizing, competitive benchmarking, and channel-partner planning:

By Type of Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)

By Type of Sample

• Blood
• Other Samples

By Type of Circulating Biomarker

• Circulating Tumor DNA (ctDNA)
• Cell-Free DNA (cfDNA)
• Cell-Free RNA (cfRNA)
• Exosomes
• Other Circulating Biomarkers

By Type of Cancer

• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Lung Cancer
• Bladder Cancer
• Melanoma
• Thyroid Cancer
• Gastric Cancer
• Head and Neck Cancer
• Leukemia
• Brain Cancer
• Liver Cancer
• Cervical Cancer
• Ovarian Cancer
• Esophageal Cancer
• Pancreatic Cancer
• Nasopharyngeal Cancer
• Sarcoma

By Application Area

• Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring

By End User

• Hospitals / Laboratories
• Research Institutes
• Other End Users

North America Liquid Biopsy Market: Key Segment Insights

Next-Generation Sequencing Leads Technology Adoption

Next-generation sequencing currently accounts for the largest market share and is likely to remain dominant in the future. This high share reflects its ability to simultaneously detect single nucleotide variants, insertions/deletions, copy number variations, and gene fusions from a single blood draw. This multi-marker capability makes NGS the technology of choice for comprehensive genomic profiling, therapy selection, and MRD monitoring. Continued improvements in sequencing accuracy, turnaround time, and cost are expected to sustain NGS's lead through the forecast period, even as PCR-based assays remain relevant for faster, lower-cost, single-marker testing needs.

Blood Remains the Dominant Sample Type

Presently, the blood segment occupies the highest share of the market. Blood is the preferred specimen type for liquid biopsy testing, supported by well-established venipuncture infrastructure, reliable plasma-derived ctDNA and cfDNA yield, and the practicality of repeat sample collection for longitudinal monitoring. Other sample types, including urine and cerebrospinal fluid, remain niche but are gaining research interest for select indications such as bladder and central nervous system cancers.

Increase in Circulating Tumor DNA Anchors Biomarker-Level Demand

Currently, circulating tumor DNA holds the largest share among circulating biomarker types. This high share is likely due to its established clinical utility in detecting actionable mutations for therapy selection and in tracking minimal residual disease after treatment. Cell-free RNA and exosome-based approaches are gaining momentum as complementary or multi-analyte tools, particularly for early-detection assays that combine multiple biomarker classes with AI-based signal interpretation.

Breast Cancer Leads by Cancer Type, Pancreatic Cancer is Likely to Register Higher CAGR

Breast cancer currently accounts for the highest market share. This high share is likely because of high disease incidence and the extensive use of biomarker-driven treatment strategies. Molecular profiling for mutations such as PIK3CA and ESR1 is now central to selecting targeted therapies in advanced breast cancer. Further, the reliance on genomic testing combined with FDA-approved companion diagnostics and strong clinical-trial activity reinforces the segment's leading position.

Pancreatic cancer is expected to register the highest CAGR during the forecast period. This lucrative growth is largely because pancreatic tumors are often diagnosed late and are anatomically difficult to biopsy via tissue sampling. Liquid biopsy is increasingly viewed as a practical alternative for molecular profiling, treatment selection, and disease monitoring in this high-unmet-need indication.

Early Diagnosis Leads Application Area, Monitoring Segments Gain Share in the Future

Early diagnosis currently represents the largest application area share. This high share is driven by the expanding usage of blood-based screening tests for colorectal cancer and multi-cancer early detection. At the same time, patient-monitoring and recurrence-monitoring applications largely powered by ctDNA-based MRD assays are growing quickly as post-treatment surveillance becomes a standard part of oncology care pathways.

Hospitals and Laboratories Remain the Primary End Users

Hospitals and laboratories account for the largest share of end-user demand. This high share reflects the integration of liquid biopsy into routine oncology diagnostic and monitoring workflows. Research institutes represent a smaller but steadily growing share of demand, tied to biomarker discovery programs and clinical-trial-linked testing.

Example Players in the North America Liquid Biopsy Market

• DiaCarta
• Exact Sciences
• Integrated DNA Technologies
• nRICH dx
• Precipio
• Thermo Fisher Scientific

Expert Interview and Industry Insights

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:

• Chairman, Small Company, US
• Founder and Chief Executive Officer, Small Company, India
• Chief Executive Officer, Small Company, Australia
• Founder, President and Chief Technology Officer, Small Company, US
• Chief Operating Officer and Co-Founder, Small Company, Canada
• Chief Medical Officer, Mid-sized Company, US
• Chief Scientific Officer, Mid-sized Company, US
• Founder and Medical Director, Small Company, Germany
• Founder, Small-sized Company, Sweden
• Innovation Director, Mid-sized Company, Spain
• Director, Mid-sized Company, US
• Former Chief Executive Officer and Co-founder, Small-sized Company, US
• Former Chief Executive Officer, Mid-sized Company, US
• Former Founder, Small-sized Company, US
• Former Marketing Director, Mid-sized Company, Belgium
• Former Strategic Technology Advisor, Small Company, Australia
• Former Sales and Marketing Manager, Small Company, Italy

NORTH AMERICA LIQUID BIOPSY MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: Detailed market opportunity analysis across technology, sample type, biomarker, cancer type, application area, and end user.
• Competitive Benchmarking: Detailed assessment of active liquid biopsy developers, including platform capabilities, regulatory status, and geographic reach.
• Regulatory and Reimbursement Mapping: Coverage of FDA approval pathways, payer-coverage decisions, and state-level laboratory authorizations across the US and Canada.
• Company Profiles: In-depth profiles of established and emerging players, covering year of establishment, headquarters, platform portfolio, and recent initiatives.
• Partnerships and Collaborations Analysis: Tracking of licensing deals, co-marketing agreements, and distribution partnerships across the value chain.
• Funding and Investment Analysis: Review of financing activity, including funding type, amount, purpose, and most active investors.
• Recent Expansion Tracking: Analysis of new facility investments, lab-capacity expansions, and geographic footprint changes.
• SWOT Analysis: A strategic evaluation of the market's strengths, weaknesses, opportunities, and threats, with actionable implications for channel strategy.

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections for North America Liquid Biopsy Market and its constituent sub-segments, valuable to both established market leaders and emerging entrants.
• It offers stakeholders a well-rounded overview of the market, including key drivers, barriers, opportunities, and challenges, empowering data-driven decision-making.
• It helps businesses identify future opportunities and assess whether those opportunities are worth pursuing.
• It supports demand identification by clarifying the needs, preferences, and behavior of the target customer base, enabling more effective service and capability positioning.
• It enables more effective communication with prospective partners and clients, and supports the development of stronger business relationships across the industry.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How large is the North America liquid biopsy market today, and how fast is it growing?
• Which technologies, cancer types, and application areas hold the largest share of the market?
• Which companies lead the competitive landscape, and what are their flagship platforms?
• What are the primary growth drivers and challenges shaping market evolution?
• What recent regulatory approvals, launches, and reimbursement decisions are shaping near-term demand?
• What opportunities exist for distributors, logistics providers, and channel partners entering this space?